



Partnering in the AI Era: Navigating AI's Impact and Opportunities with Patient Advocacy Groups

Deepa Dahal
Co-Founder & Partner, DKI Health

Contact: deepa.dahal@dkihealth.com

From advocacy to algorithms: Patient organizations are beginning to embrace artificial intelligence.



HOW GENERATIVE ARTIFICIAL INTELLIGENCE IS CHANGING PATIENT ADVOCACY



New AI Tool Improves the Accuracy of a Breast Cancer Prognosis



HealthTree Foundation
Launches AI-Powered
Personalized Clinical Trial
Finder




A new grant will support
the integration of AI to
enhance data analytics...



**Crohn's & Colitis Foundation's
IBD Ventures Invests in Mobius
Care to Advance AI-Powered
Precision Medicine for IBD**

We wanted to understand how PAGs are using AI, and how pharma can partner on patient-centered solutions.

Secondary Research

- 42 PAGs reviewed, with 



Primary Research

- 12 Advocacy Leaders: 15-min written survey + 60-min Zoom interviews



- 3 Pharma Executives: 30-60 min Zoom interviews


Our discussions focused on current use, potential opportunities, risk management, and pharma partnerships.

Key Questions

1. How are you using AI tools and technologies?
2. Where do you see the biggest opportunities?
3. What risks/concerns are important to address?
4. Which areas should avoid AI intervention in decision-making, if any?
5. How do you hope to work with pharma and biotech on utilizing AI?

AI is most used by PAGs for patient education/support, clinical research, and early detection and diagnosis.


Number of Patient Organizations Reporting AI Use for Each Purpose (N=45)



Note: This chart is based on DKI Health’s analysis of the data reviewed and insights from interviews; some purposes may overlap and/or be categorized differently.

Several advocacy leaders report using various AI tools to enhance their daily work.

Daily Use of AI Tools by Advocacy Leaders (N=12)



"80% of our staff use AI every day. We embed Boodle.AI into everything we do... there's not a single thing that I write from scratch anymore. We use it for a lot of content, analysis, program development and grant writing... we use it all the time."

Courtney Bugler
ZERO PROSTATE CANCER

"We're using AI for grant writing, developing objectives, simplifying medical language, translating materials, and personalizing content. We're also exploring a newsletter system that aggregates info to better tailor updates for our members"

Sue Koob
PCNA


Reasons for not using AI?

"Not prioritized in my current work"

"Not necessary for our advocacy efforts"

They are excited about the potential of AI for patients.

Potential of AI Tools to Benefit Patients (N=12)



"AI helps bridge the gap between patients and doctors. It helps patients express concerns clearly and allows doctors to better understand their experience, improving healthcare overall"

Alisha Lewis
SICKLE CELL ADVOCATE

"Our goal is not to save money for payers, but to improve the lives of cancer patients and their families. So that's how we want to see AI tools used..."

Jen Grand-Lejano
ACS CAN

Key risks and concerns must be addressed.

Average Level of Concerns about AI for Patients (N=12)

(On a scale of 1-3, where 1= not concerned and 3=very concerned).

Most Concerned

2.9 **Bias and misinformation** in AI algorithms due to biased/inaccurate training data

2.8 **Lack of clear regulations and policies** protecting patient rights and interests

2.5 **Loss of human connection**/empathy/lived patient experience

2.5 **Data quality, privacy, and security** – affecting ability to provide informed consent

2.4 **Lack of patient trust** in AI-generated health information

2.3 **Lack of transparency** in AI decision-making, making it challenging to assess errors

1.8 **High energy consumption** – environmental impact of AI technologies

1.7 **Increase in health inequities**, based on limited access to AI tools (older, rural...)

Least Concerned

1.6 **Risk of HCPs losing influence** or credibility and impacting patient-HCP relationship

"AI is not a doctor, and it's not always reliable—especially in rare disease. If it's getting this much wrong for SMA, which is well-known, it's likely even worse for other rare diseases"


Arya Singh
SMA PATIENT/ADVOCATE

"We do see a challenge in AI not getting it right... trust is an issue, so we have to go slow. We'll follow some of the bigger organizations that are going to move forward with this"


Phil Gattone
NBDF

Governance is necessary – and several organizations are driving development of patient-centered principles for AI.


National Academy of Medicine



The Light Collective



Coalition for Health AI (CHAI)



+ 4 Industry Leaders
+ 19 Health Systems

Pharma-PAG collaborations on AI are in early stages...



Partnered in the **ALDER trial** to evaluate a potential therapy for recurrent *C. difficile* infections (REC-3964)

"There are all these molecules but no one knows what they can do or which diseases they'd be effective in, so Recursion was using AI to identify potential treatments for C.diff"

Christian John Lillis
PEGGY LILLIS FOUNDATION



Collaborated on the development of **EczemaLess**, an app that leverages AI to track and manage Atopic Dermatitis




Zero is developing an AI-enabled prostate cancer patient support and navigation tool for patients, care partners, and at-risk communities using SMS texting as part of its **"Blitz the Barriers"** initiative

"Novartis is leaning in, doubling down in investing in a lot of cool things, including supporting our use and expansion of AI tools"

Courtney Bugler
ZERO PROSTATE CANCER























But companies are investing heavily, as AI is expected to accelerate drug development and enhance productivity.

“GenAI may drive \$60 to \$110 billion annually for pharmaceutical and medical-product industries”
McKinsey



*Index calculated based on talent, innovation and execution of AI by [Statista](#)

Many of the AI technologies impact patient care, from drug discovery to patient engagement and reach.

Purpose	Select AI Tools	Adoption by Pharma [A Snapshot]
1 Drug Discovery & Development	"TEMPUS  Benevolent ^{AI}	   
2 Clinical Trial Optimization	 	 
3 Manufacturing & Supply Chain		
4 Early Disease Detection		  
5 Patient Care & Engagement	 	 
6 Patient Data Analytics	"TEMPUS Benevolent ^{AI}	
7 Content Creation & Marketing	  [PERSADO]	Multiple pharma companies

Key takeaways and recommendations for pharma



Unlock Shared AI Opportunities

Identify and scale shared AI use cases through strategic partnerships with PAGs.



Integrate Patient Input Into AI Across Functions

Embed patient and advocacy insights in AI technology adoption across all functions, from R&D and Commercial through Manufacturing and Access.



Adopt Best Practices for AI Governance

Integrate policies and guidance from leading health technology, medical, and patient organizations to incorporate best practices in AI development and deployment.



DKI
HEALTH

**A Patients-First Global Healthcare Strategy Consultancy.
Certified Women-Owned Small Business.**

Contact Us

DEEPA DAHAL

Executive Partner

deepa.dahal@dkihealth.com

+1.646.357.9477

KAREN DINDIAL

Executive Partner

karen.dindial@dkihealth.com

+1.646.357.9466

228 Park Ave South
Suite 28653
New York, NY 10017
www.dkihealth.com

New York City | Seattle | Bangalore

Connect



Select Endorsements



Small/Women-Owned Business Certifications

